ZOLL Medical Corporation (Nasdaq: ZOLL) 16.4% LOWER; today announced that preliminary revenues for Q2 were approximately $90-$92 million, down approximately 8% from revenues in the same period last year. The Company’s revenues fell short of expectations primarily due to lower than expected sales to the North American hospital market including less than expected military revenues. Additionally, revenues from the sale of AEDs were lower than anticipated. The Company estimates that EPS for the quarter will be in the range of $0.05-$0.10, falling below the consensus earnings estimate of $0.24. The Street is currently expecting Q2 sales of $101.43 million,